Neuphoria Therapeutics Inc. Share Price & Technical Analysis
NEUP · $5.48 (+7.03%)
Healthcare / Biotechnology
$5.48
+7.03%
Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, discovers and develops novel allosteric ion channel modulators for the treatment of central nervous system disorders in Australia. Its lead product candidate includes BNC210, a selective negative allosteric modulator of the a7 for the treatment of social anxiety disorder; and is phase 2b to treat post-traumatic stress disorde…
Price chart
Seasonality
May has 3 positive and 2 negative years (last 5 years shown)
4% return in May, 3% avg return in past 3 year May month.
33% return in 2026, -43% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 3% | 5% | -5% | 26% | 4% | – | – | – | – | – | – | – | 33% |
| 25 | 43% | 2% | 12% | -11% | 22% | 4% | 13% | 41% | 4% | -61% | -2% | -11% | 56% |
| 24 | -34% | 30% | -15% | -5% | -11% | -9% | 2% | -4% | -28% | -57% | 50% | -3% | -85% |
| 23 | -11% | -28% | -13% | -14% | -2% | -3% | -25% | 10% | 43% | -22% | -45% | 11% | -100% |
| 22 | -11% | -10% | -17% | 3% | 4% | -7% | -6% | 18% | -25% | 6% | -15% | -33% | -94% |
Monthly return % by calendar month · historical pattern, not a forecast
Neutral · Emerging · Strong
Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, discovers and develops novel allosteric ion channel modulators for the treatment of central nervous system disorders in Australia. Its lead product candidate includes BNC210, a selective negative allosteric modulator of the a7 for the treatment of social anxiety disorder; and is phase 2b to treat post-traumatic stress disorder. The company also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105 for the treatment of cancer. In addition, it develops NextGen, which is in preclinical trial for the treatment of multiple central nervous system indications; and Kv3.1/3.2 agonist, which is in preclinical trial to treat potential cognitive deficits and negative symptoms/social withdrawal in schizophrenia and autism spectrum disorders. The company has a collaboration with Merck & Co., Inc. to develop a7 receptor positive allosteric modulators targeting cognitive dysfunction associated with alzheimer's disease and other central nervous system conditions. The company was formerly known as Bionomics Limited and changed its name Neuphoria Therapeutics Inc. in December 2024. Neuphoria Therapeutics Inc. was incorporated in 1996 and is based in Burlington, Massachusetts.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$27.01M
P/E ratio
—
52W high
$21.40
52W low
$3.65
Volume
1,34,026
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Neuphoria Therapeutics Inc. share price today?
- Neuphoria Therapeutics Inc. (NEUP) last traded around $5.48 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does NEUP have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for NEUP. Download the app for real-time alerts.
- How can I analyze Neuphoria Therapeutics Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.